23 August 2023
RUA Life Sciences plc
("RUA" the "Company" or the "Group")
Result of AGM
RUA Life Sciences plc (AIM:RUA.L), the holding company of a group of medical device businesses focussed on the exploitation of the world's leading long-term implantable biostable polymer (Elast-Eon ™), announces that all resolutions put forward to its Annual General Meeting held earlier today were duly passed and the votes cast were as follows:
| Res No. | Votes For | % | Votes Against | % | Votes Total | % I.S.C. | Votes Withheld |
| 1 | 3,120,357 | 100.00% | 0 | 0.00% | 3,120,357 | 14.07 | 0 |
| 2 | 2,229,757 | 71.48% | 889,792 | 28.52% | 3,119,549 | 14.06 | 808 |
| 3 | 2,955,917 | 95.24% | 147,790 | 4.76% | 3,103,707 | 13.99 | 16,650 |
| 4 | 2,951,476 | 95.23% | 147,790 | 4.77% | 3,099,266 | 13.97 | 21,091 |
| 5 | 3,093,484 | 99.67% | 10,223 | 0.33% | 3,103,707 | 13.99 | 16,650 |
| 6 | 2,980,778 | 95.53% | 139,356 | 4.47% | 3,120,134 | 14.06 | 223 |
| 7 | 2,980,448 | 95.53% | 139,569 | 4.47% | 3,120,017 | 14.06 | 340 |
| 8 | 2,951,597 | 95.48% | 139,569 | 4.52% | 3,091,166 | 13.93 | 29,191 |
The full text of each of the resolutions is set out in the notice of Annual General Meeting, copies of which are available on the Company's website (www.rualifesciences.com).
QCA Code - statement regarding voting result
The board notes that although Resolution 2 (remuneration committee report) passed with the requisite majority, it received more than 20% of votes against the board's recommendation. We thank shareholders for their support and the Board will look to continue engagement throughout the year. The board encourages an open and constructive dialogue directly with shareholders and continue to be willing to engage with any shareholder on any relevant topics should they so wish.
For further information contact:
RUA Life Sciences
Bill Brown, Chairman Tel: +44 (0)1294 317073
Dr Caroline Stretton, Group MD Tel: +44 (0)1294 317073
Cenkos Securities plc (Nominated Adviser and Broker) Tel: +44 (0)20 7397 8900
Giles Balleny / Max Gould (Corporate Finance)
Michael Johnson (Sales)
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
